ASGR1 and metabolic dysfunction-associated steatotic liver disease: Targeted transport of STK25 antisense oligonucleotide (STK25 ASO), which could selectively bind to the Asialoglycoprotein receptor (ASGPR) expressed on the surface of hepatocytes, reduced oxidative stress in the hepatocytes, improved mitochondrial function and inhibited the expression of adipogenic genes and Acetyl-CoA carboxylase (ACC) in the liver, thus delaying the development of NAFLD [27].